Caroline Kuhlman, NP

Articles

Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma

February 14th 2024

Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.

FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

February 14th 2024

Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.

Navigating FGFRi Therapy Adverse Effects: Nail Toxicities

February 7th 2024

Experts share preventative and management strategies for nail toxicities and mouth sores that can cause significant quality of life issues for patients being treated with FGFRi.

Monitoring and Managing Hyperphosphatemia

February 7th 2024

Hyperphosphatemia is the most common AE associated with FGFRi treatments and can impact patient quality of life, but there are treatments and possible diet changes that may help mitigate this AE.

Symptoms Associated With Eye-Related Toxicities Amid FGFRi Therapy

January 31st 2024

Ocular toxicities from dry eye to development of cataracts are potential risks with FGFRi treatment; providers share management strategies.

Patient Perspective Regarding FGFRi Adverse Event Profiles

January 31st 2024

A patient with cholangiocarcinoma shares her experience while being treated with an FGFR inhibitor, as well as insights on what providers should tell their patients to help them best manage or possibly prevent these adverse events.

Common Adverse Events Associated With FGFRi Therapy

January 24th 2024

A review of how frequently adverse events from hyperphosphatemia to nail toxicities to stomatitis and more.

Key Highlights For Patient Education Surrounding FGFR Inhibitors

January 24th 2024

Provider perspectives on the importance of education patients about potential adverse events they may experience when initiating treatment with FGFR inhibitors.

Next-Gen Inhibitors Shaping Cholangiocarcinoma Treatment Landscape

January 18th 2024

Next-generation FGFR inhibitors show promise in early trials evaluating their efficacy and safety for the treatment of cholangiocarcinoma.

First- and Second-Line Treatment Options for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions or Alterations

January 18th 2024

Experts discuss treatment options for cholangiocarinoma and how FGFR inhibitors have changed the treatment landscape in recent years.

The Role of Biomarker Testing in Diagnosing Cholangiocarcinoma

January 10th 2024

Experts in treating cholangiocarcinoma share insights on when biomarker testing is needed and which biomarkers to test for.

Clinical Presentations of Patients With Cholangiocarcinoma

January 10th 2024

Key opinion leaders illustrate how patients with intrahepatic cholangiocarcinoma present in a clinical setting.

Risk Factors Leading to Various Liver Cancers

January 10th 2024

The intricate web of risk factors influencing diverse forms of liver cancers are explored.

Intrahepatic Cholangiocarcinoma Overview

December 14th 2023

Medical experts discuss the pathology of intrahepatic cholangiocarcinoma.